Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

• DOI: 10.1007/s10620-022-07817-w
• Publication Date: 2023-02-03T18:04:07Z
• Authors: Beatriz Mateos-Muñoz; María Buti; Inmaculada Fernán...; Marta Hernández C...; Vanesa Bernal-Mon...; Fernando Díaz-Fon...; Rosa María Morillas; Luisa García-Buey; Ester Badía; Mireia Miquel; Alberto Amador-Na...; Sergio Rodríguez-...; Lucía Ramos-Merino; Antonio Madejón; Montserrat García...; Juan Ignacio Arenas; Joaquín Cabezas; Jesús Manuel Gonz...; Conrado Fernández...; Patricia Cordero; Moisés Diago; Antonio Mancebo; Alberto Pardo; Manuel Rodríguez; Elena Hoyas; Jose Javier Moreno; Juan Turnes; Miguel Ángel Simón; Cristina Marcos-F...; Jose Luis Calleja; Rafael Bañares; Sabela Lens; Javier Garcia-Sam...; Javier Crespo; Manuel Romero-Gomez; Francisco Gea; Enrique Rodríguez...; Santiago Moreno; Agustin Albillos
• Keywords: Entecavir; Emtricitabine; Hepatitis B; Tenofovir

HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity in with chronic hepatitis B (CHB) TDF or entecavir (ETV). Spanish hospital databases (n = 28) including information regarding adult CHB ETV for period February 1st November 30th 2020 were searched COVID-19, defined as positive SARS-CoV-2 polymerase chain reaction, severe COVID-19. Of 4736 patients, 117 had (2.5%), 67 50 ETV. Compared TDF, showed (p < 0.05) greater rates obesity, diabetes, ischemic cardiopathy, hypertension. incidence similar both groups (2.3 vs. 2.6%). more often 0.01) (36 6%), required intensive care unit (ICU) (10% 0) ventilatory support (20 3%), hospitalized longer (10.8 ± 19 3.1 7 days) died (10 1.5%, p 0.08). In an IPTW propensity score analysis adjusted age, sex, comorbidities, fibrosis stage, associated sixfold reduction (adjusted-IPTW-OR 0.17, 95%CI 0.04–0.67, 0.01). ETV, seems play protective role whereby is lowered.